

Gabriel Herrero-Beaumont

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3947812/publications.pdf>

Version: 2024-02-01

179
papers

11,978
citations

47006
47
h-index

28297
105
g-index

184
all docs

184
docs citations

184
times ranked

10454
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 1145-1155.	0.9	1,661
2	EULAR evidence based recommendations for the management of hand osteoarthritis: Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 377-388.	0.9	738
3	EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 669-681.	0.9	704
4	EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 483-489.	0.9	499
5	EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). <i>Annals of the Rheumatic Diseases</i> , 2000, 59, 936-944.	0.9	458
6	An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 337-350.	3.4	392
7	Glucosamine inhibits IL-1 β -induced NF κ B activation in human osteoarthritic chondrocytes. <i>Osteoarthritis and Cartilage</i> , 2003, 11, 290-298.	1.3	341
8	2018 update of the EULAR recommendations for the management of hand osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 16-24.	0.9	273
9	Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: A randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. <i>Arthritis and Rheumatism</i> , 2007, 56, 555-567.	6.7	248
10	Osteoarthritis associated with estrogen deficiency. <i>Arthritis Research and Therapy</i> , 2009, 11, 241.	3.5	236
11	Subchondral bone as a key target for osteoarthritis treatment. <i>Biochemical Pharmacology</i> , 2012, 83, 315-323.	4.4	220
12	Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 3928-3939.	6.7	194
13	Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 759-766.	0.9	190
14	TLR4 signalling in osteoarthritisâ€”finding targets for candidate DMOADs. <i>Nature Reviews Rheumatology</i> , 2015, 11, 159-170.	8.0	188
15	Subchondral bone microstructural damage by increased remodelling aggravates experimental osteoarthritis preceded by osteoporosis. <i>Arthritis Research and Therapy</i> , 2010, 12, R152.	3.5	180
16	A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1957-1962.	0.9	159
17	Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say?. <i>Drugs and Aging</i> , 2019, 36, 15-24.	2.7	146
18	High-resolution MRI detects cartilage swelling at the early stages of experimental osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2001, 9, 463-472.	1.3	141

#	ARTICLE	IF	CITATIONS
19	A Sonographic Enthesitic Index of lower limbs is a valuable tool in the assessment of ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1015-1019.	0.9	140
20	Primary Osteoarthritis No Longer Primary: Three Subsets with Distinct Etiological, Clinical, and Therapeutic Characteristics. <i>Seminars in Arthritis and Rheumatism</i> , 2009, 39, 71-80.	3.4	130
21	Histopathological correlation of cartilage swelling detected by magnetic resonance imaging in early experimental osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2004, 12, 878-886.	1.3	120
22	Bone mineral measurements of subchondral and trabecular bone in healthy and osteoporotic rabbits. <i>Skeletal Radiology</i> , 2006, 35, 34-41.	2.0	118
23	Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2004, 12, 263-268.	1.3	117
24	Why we should definitely include intra-articular hyaluronic acid as a therapeutic option in the management of knee osteoarthritis: Results of an extensive critical literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 563-572.	3.4	110
25	Type 2 diabetes mellitus and osteoarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 9-19.	3.4	110
26	Osteoporosis increases the severity of cartilage damage in an experimental model of osteoarthritis in rabbits. <i>Osteoarthritis and Cartilage</i> , 2007, 15, 69-77.	1.3	102
27	Characterization of a new experimental model of osteoporosis in rabbits. <i>Journal of Bone and Mineral Metabolism</i> , 2008, 26, 53-59.	2.7	99
28	Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis. <i>Osteoarthritis and Cartilage</i> , 2011, 19, 1228-1236.	1.3	98
29	Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study. <i>Clinical Therapeutics</i> , 2004, 26, 245-256.	2.5	97
30	Use of Intraarticular Hyaluronic Acid in the Management of Knee Osteoarthritis in Clinical Practice. <i>Arthritis Care and Research</i> , 2017, 69, 1287-1296.	3.4	95
31	Combined Treatment With Chondroitin Sulfate and Glucosamine Sulfate Shows No Superiority Over Placebo for Reduction of Joint Pain and Functional Impairment in Patients With Knee Osteoarthritis: A Sixâ€Month Multicenter, Randomized, Doubleâ€Blind, Placeboâ€Controlled Clinical Trial. <i>Arthritis and Rheumatology</i> , 2017, 69, 77-85.	5.6	94
32	A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 64-69.	0.9	90
33	Lipid Transport and Metabolism in Healthy and Osteoarthritic Cartilage. <i>International Journal of Molecular Sciences</i> , 2013, 14, 20793-20808.	4.1	89
34	Osteoarthritis: a progressive disease with changing phenotypes. <i>Rheumatology</i> , 2014, 53, 1-3.	1.9	87
35	Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Epidemiology and Phenotype of Osteoarthritis. <i>Drugs and Aging</i> , 2015, 32, 179-187.	2.7	82
36	The Increase in O-Linked N-Acetylglucosamine Protein Modification Stimulates Chondrogenic Differentiation Both in Vitro and in Vivo. <i>Journal of Biological Chemistry</i> , 2012, 287, 33615-33628.	3.4	80

#	ARTICLE	IF	CITATIONS
37	Targeting chronic innate inflammatory pathways, the main road to prevention of osteoarthritis progression. <i>Biochemical Pharmacology</i> , 2019, 165, 24-32.	4.4	72
38	Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 998-1005.	0.9	70
39	Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2005, 13, 13-19.	1.3	62
40	Mecanismo de acción de abatacept: concordancia con su perfil clínico. <i>Reumatología Clínica</i> , 2012, 8, 78-83.	0.5	62
41	Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. <i>Agents and Actions</i> , 1994, 41, 171-178.	0.7	61
42	Characterization of multinucleated giant cells in synovium and subchondral bone in knee osteoarthritis and rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 226.	1.9	61
43	Ultrasonographic assessment of Baker's cysts after intra-articular corticosteroid injection in knee osteoarthritis. <i>Journal of Clinical Ultrasound</i> , 2006, 34, 113-117.	0.8	55
44	Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors. <i>Arthritis and Rheumatism</i> , 2009, 60, 2558-2564.	6.7	55
45	Citrullination enhances the pro-inflammatory response to fibrin in rheumatoid arthritis synovial fibroblasts. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1400-1406.	0.9	52
46	Analysis of TNFAIP3, a feedback inhibitor of nuclear factor- κ B and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility. <i>Arthritis Research and Therapy</i> , 2009, 11, R42.	3.5	51
47	Clinical settings in knee osteoarthritis: Pathophysiology guides treatment. <i>Maturitas</i> , 2017, 96, 54-57.	2.4	51
48	SDF-1 signaling: a promising target in rheumatic diseases. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 1077-1087.	3.4	50
49	Mediators and Patterns of Muscle Loss in Chronic Systemic Inflammation. <i>Frontiers in Physiology</i> , 2018, 9, 409.	2.8	50
50	Effect of a high dose of glucosamine on systemic and tissue inflammation in an experimental model of atherosclerosis aggravated by chronic arthritis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009, 297, H268-H276.	3.2	49
51	RANKL synthesized by articular chondrocytes contributes to juxta-articular bone loss in chronic arthritis. <i>Arthritis Research and Therapy</i> , 2012, 14, R149.	3.5	49
52	Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis. <i>British Journal of Pharmacology</i> , 2008, 154, 843-851.	5.4	47
53	Bone mineral density and joint cartilage: four clinical settings of a complex relationship in osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1523-1525.	0.9	47
54	Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement. <i>Osteoarthritis and Cartilage</i> , 2015, 23, 2086-2093.	1.3	47

#	ARTICLE	IF	CITATIONS
55	<sc>PTH</sc> [1â€³4] enhances bone response around titanium implants in a rabbit model of osteoporosis. Clinical Oral Implants Research, 2013, 24, 1027-1034.	4.5	46
56	A fibrin based model for rheumatoid synovitis. Annals of the Rheumatic Diseases, 2003, 62, 1135-1138.	0.9	45
57	Ectopic calcification among families in the Azores: Clinical and radiologic manifestations in families with diffuse idiopathic skeletal hyperostosis and chondrocalcinosis. Arthritis and Rheumatism, 2006, 54, 1340-1349.	6.7	44
58	Increased synovial lipodystrophy induced by high fat diet aggravates synovitis in experimental osteoarthritis. Arthritis Research and Therapy, 2017, 19, 264.	3.5	44
59	Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis. Osteoarthritis and Cartilage, 2008, 16, 1484-1493.	1.3	43
60	Commentary: osteoarthritis of the knee and glucosamine. Osteoarthritis and Cartilage, 2006, 14, 963-966.	1.3	42
61	Nonsteroidal antiinflammatory drugs and prostaglandin E₂ modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe knee osteoarthritis. Arthritis and Rheumatism, 2010, 62, 478-488.	6.7	42
62	EP2/EP4 signalling inhibits monocyte chemoattractant protein-1 production induced by interleukin 1Î in synovial fibroblasts. Annals of the Rheumatic Diseases, 2004, 63, 1197-1204.	0.9	40
63	Genetic variation in the nuclear factor Î² pathway in relation to susceptibility to rheumatoid arthritis. Annals of the Rheumatic Diseases, 2009, 68, 579-583.	0.9	40
64	Efficacy and safety of a selective estrogen receptor Î² agonist, ERBâ€³41, in patients with rheumatoid arthritis: A 12â€³week, randomized, placeboâ€³controlled, phase II study. Arthritis Care and Research, 2010, 62, 1588-1593.	3.4	40
65	An update on the up and coming therapies to treat osteoarthritis, a multifaceted disease. Expert Opinion on Pharmacotherapy, 2016, 17, 1745-1756.	1.8	39
66	Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis. British Journal of Pharmacology, 2017, 174, 3018-3031.	5.4	38
67	6â€³Shogaol inhibits chondrocytesâ€³ innate immune responses and cathepsinâ€³ activity. Molecular Nutrition and Food Research, 2014, 58, 256-266.	3.3	37
68	Osteoporotic OA: a reasonable target for bone-acting agents. Nature Reviews Rheumatology, 2013, 9, 448-450.	8.0	34
69	Treat-to-target strategy for knee osteoarthritis. International technical expert panel consensus and good clinical practice statements. Therapeutic Advances in Musculoskeletal Disease, 2019, 11, 1759720X1989380.	2.7	34
70	Modulation of cell recruitment by anti-inflammatory agents in antigen-induced arthritis. Annals of the Rheumatic Diseases, 2002, 61, 1027-1030.	0.9	32
71	Diacerein has a weak effect on the catabolic pathway of human osteoarthritis synovial fibroblastâ€³comparison to its effects on osteoarthritic chondrocytes. Rheumatology, 2008, 47, 627-633.	1.9	32
72	Differential effects of the antioxidant n-acetylcysteine on the production of catabolic mediators in IL-1Î²-stimulated human osteoarthritic synoviocytes and chondrocytes. European Journal of Pharmacology, 2009, 623, 125-131.	3.5	32

#	ARTICLE	IF	CITATIONS
73	Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. <i>International Journal of Clinical Practice</i> , 2010, 64, 756-762.	1.7	32
74	Correlation between arthroscopic and histopathological grading systems of articular cartilage lesions in knee osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2009, 17, 205-212.	1.3	31
75	An OA phenotype may obtain major benefit from bone-acting agents. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 421-428.	3.4	31
76	Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty. <i>Drugs and Aging</i> , 2015, 32, 525-535.	2.7	31
77	Dynamic ultrasound assessment of medial meniscal subluxation in knee osteoarthritis. <i>Rheumatology</i> , 2013, 52, 1443-1447.	1.9	30
78	Selective estrogen receptor modulators (SERMs): New alternatives for osteoarthritis?. <i>Maturitas</i> , 2014, 77, 380-384.	2.4	30
79	Criterion validity of ultrasound in the identification of calcium pyrophosphate crystal deposits at the knee: an OMERACT ultrasound study. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 261-267.	0.9	30
80	Fibrin generated in the synovial fluid activates intimal cells from their apical surface: a sequential morphological study in antigen-induced arthritis. <i>British Journal of Rheumatology</i> , 2003, 42, 19-25.	2.3	28
81	Abatacept Mechanism of Action: Concordance With Its Clinical Profile. <i>Reumatología Clínica (English)</i> Tj ETQq1 1 0,784314,rgBT /O	0.3	28
82	O-linked N-acetylglucosamine (O-GlcNAc) protein modification is increased in the cartilage of patients with knee osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2014, 22, 259-263.	1.3	28
83	PTH Increases Jaw Mineral Density in a Rabbit Model of Osteoporosis. <i>Journal of Dental Research</i> , 2010, 89, 360-365.	5.2	27
84	Hypercholesterolemia boosts joint destruction in chronic arthritis. An experimental model aggravated by foam macrophage infiltration. <i>Arthritis Research and Therapy</i> , 2013, 15, R81.	3.5	27
85	Chronic arthritis aggravates vascular lesions in rabbits with atherosclerosis: A novel model of atherosclerosis associated with chronic inflammation. <i>Arthritis and Rheumatism</i> , 2008, 58, 2723-2734.	6.7	26
86	Effects of estrogen deficiency and low bone mineral density on healthy knee cartilage in rabbits. <i>Journal of Orthopaedic Research</i> , 2010, 28, 812-818.	2.3	26
87	Targeting subchondral bone in osteoporotic osteoarthritis. <i>Arthritis Research and Therapy</i> , 2014, 16, 494.	3.5	26
88	Tenofovir Causes Bone Loss via Decreased Bone Formation and Increased Bone Resorption, Which Can Be Counteracted by Dipyrindamole in Mice. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 923-938.	2.8	26
89	Physiological effects of oral glucosamine on joint health: current status and consensus on future research priorities. <i>BMC Research Notes</i> , 2013, 6, 115.	1.4	25
90	The adipokine lipocalin-2 in the context of the osteoarthritic osteochondral junction. <i>Scientific Reports</i> , 2016, 6, 29243.	3.3	25

#	ARTICLE	IF	CITATIONS
91	Guidelines for the conduct of pharmacological clinical trials in hand osteoarthritis: Consensus of a Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 1-8.	3.4	25
92	Description of a new family with cryopyrin-associated periodic syndrome: risk of visual loss in patients bearing the R260W mutation. <i>Rheumatology</i> , 2014, 53, 1095-1099.	1.9	24
93	Recessive mutations in muscle-specific isoforms of FXR1 cause congenital multi-minicore myopathy. <i>Nature Communications</i> , 2019, 10, 797.	12.8	24
94	Prevalence of spondyloarthritis in Terceira, Azores: a population based study. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 551-553.	0.9	23
95	Compensatory anabolic signaling in the sarcopenia of experimental chronic arthritis. <i>Scientific Reports</i> , 2017, 7, 6311.	3.3	23
96	Parathyroid hormone-related protein exhibits antioxidant features in osteoblastic cells through its N-terminal and osteostatin domains. <i>Bone and Joint Research</i> , 2018, 7, 58-68.	3.6	23
97	Tenidap decreases IL-8 and monocyte chemotactic peptide-1 (MCP-1) mRNA expression in the synovial tissue of rabbits with antigen arthritis and in cultured synovial cells. <i>Clinical and Experimental Immunology</i> , 1998, 111, 588-596.	2.6	22
98	Effects of PTH [1-34] on synoviopathy in an experimental model of osteoarthritis preceded by osteoporosis. <i>Osteoarthritis and Cartilage</i> , 2012, 20, 1619-1630.	1.3	22
99	Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis. <i>Current Medical Research and Opinion</i> , 2015, 31, 1041-1045.	1.9	22
100	The challenge of the definition of early symptomatic knee osteoarthritis: a proposal of criteria and red flags from an international initiative promoted by the Italian Society for Rheumatology. <i>Rheumatology International</i> , 2017, 37, 1227-1236.	3.0	22
101	Meniscal degeneration in human knee osteoarthritis: in situ hybridization and immunohistochemistry study. <i>Archives of Orthopaedic and Trauma Surgery</i> , 2016, 136, 175-183.	2.4	21
102	The combined therapy with chondroitin sulfate plus glucosamine sulfate or chondroitin sulfate plus glucosamine hydrochloride does not improve joint damage in an experimental model of knee osteoarthritis in rabbits. <i>European Journal of Pharmacology</i> , 2017, 794, 8-14.	3.5	21
103	Unexpected Bone Formation Produced by RANKL Blockade. <i>Trends in Endocrinology and Metabolism</i> , 2017, 28, 695-704.	7.1	20
104	Ultrasound salivary gland involvement in Sjogren's syndrome vs. other connective tissue diseases: is it autoantibody and gland dependent?. <i>Clinical Rheumatology</i> , 2020, 39, 1207-1215.	2.2	20
105	Selective IgA deficiency and spondyloarthropathy: a distinct disease?. <i>Annals of the Rheumatic Diseases</i> , 1990, 49, 636-637.	0.9	19
106	Cartilage and bone biological markers in the synovial fluid of osteoarthritic patients after hyaluronan injections in the knee. <i>Clinica Chimica Acta</i> , 2001, 308, 107-115.	1.1	19
107	Benefits of transdermal fentanyl in patients with rheumatoid arthritis or with osteoarthritis of the knee or hip: an open-label study to assess pain control. <i>Current Medical Research and Opinion</i> , 2004, 20, 1967-1977.	1.9	19
108	Involvement of platelet-activating factor and tumour necrosis factor in the pathogenesis of joint inflammation in rabbits. <i>Clinical and Experimental Immunology</i> , 2008, 88, 318-323.	2.6	19

#	ARTICLE	IF	CITATIONS
109	Chondrocyte enlargement is a marker of osteoarthritis severity. <i>Osteoarthritis and Cartilage</i> , 2019, 27, 1229-1234.	1.3	19
110	Anti-inflammatory effect of a PAF receptor antagonist and a new molecule with antiproteinase activity in an experimental model of acute urate crystal arthritis. <i>Journal of Lipid Mediators and Cell Signalling</i> , 1996, 13, 35-49.	0.9	18
111	Endothelin-1 induces loss of proteoglycans and enhances fibronectin and collagen production in cultured rabbit synovial cells. <i>European Journal of Pharmacology</i> , 1996, 302, 191-197.	3.5	18
112	Biochemical markers of bone remodeling and bone sialoprotein in ankylosing spondylitis. <i>Clinica Chimica Acta</i> , 1999, 289, 99-110.	1.1	18
113	Sequential changes of parathyroid hormone related protein (PTHrP) in articular cartilage during progression of inflammatory and degenerative arthritis. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 917-922.	0.9	18
114	Chondroitin sulfate improves synovitis in rabbits with chronic antigen-induced arthritis. <i>Osteoarthritis and Cartilage</i> , 2010, 18, S17-S23.	1.3	18
115	Arthritis in beta-thalassemia minor. <i>Arthritis and Rheumatism</i> , 1983, 26, 1292-1293.	6.7	16
116	Prostaglandin E2 receptors EP1 and EP4 are up-regulated in rabbit chondrocytes by IL-1 β , but not by TNF α . <i>Rheumatology International</i> , 2007, 27, 911-917.	3.0	16
117	Glucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1261-1263.	0.9	16
118	Lack of Association with Rheumatoid Arthritis of Selected Polymorphisms in 4 Candidate Genes: CFH, CD209, Eotaxin-3, and MHC2TA. <i>Journal of Rheumatology</i> , 2009, 36, 1590-1595.	2.0	15
119	Recommendations for the Reporting of Harms in Manuscripts on Clinical Trials Assessing Osteoarthritis Drugs: A Consensus Statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Drugs and Aging</i> , 2019, 36, 145-159.	2.7	15
120	IL-1 β and IL-6 stimulate the production of platelet-activating factor (PAF) cultured rabbit synovial cells. <i>Clinical and Experimental Immunology</i> , 2008, 99, 364-368.	2.6	14
121	Pharmacological modulation by celecoxib of cachexia associated with experimental arthritis and atherosclerosis in rabbits. <i>British Journal of Pharmacology</i> , 2010, 161, 1012-1022.	5.4	14
122	Disorganization of chondrocyte columns in the growth plate does not aggravate experimental osteoarthritis in mice. <i>Scientific Reports</i> , 2020, 10, 10745.	3.3	14
123	SAMe restores the changes in the proliferation and in the synthesis of fibronectin and proteoglycans induced by tumour necrosis factor alpha on cultured rabbit synovial cells. <i>Rheumatology</i> , 1997, 36, 27-31.	1.9	13
124	Cyclosporin A prevents the histologic damage of antigen arthritis without inducing fibrosis. <i>Arthritis and Rheumatism</i> , 2000, 43, 311.	6.7	13
125	Transdermal fentanyl for the treatment of pain caused by rheumatoid arthritis. <i>Rheumatology International</i> , 2004, 24, 325-332.	3.0	13
126	Update on the use of abatacept for the treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 599-621.	3.0	13

#	ARTICLE	IF	CITATIONS
127	Setting up distinctive outcome measures for each osteoarthritis phenotype. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2093796.	2.7	13
128	Purinergic System Signaling in Metainflammation-Associated Osteoarthritis. <i>Frontiers in Medicine</i> , 2020, 7, 506.	2.6	13
129	Massive pulmonary hemorrhage: fatal complication of systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 1985, 12, 186-7.	2.0	13
130	An experimental study of COMP (cartilage oligomeric matrix protein) in the rabbit menisci. <i>Archives of Orthopaedic and Trauma Surgery</i> , 2011, 131, 1167-1176.	2.4	12
131	Beneficial effect of fibronectin administration on chronic nephritis in rats. <i>Arthritis and Rheumatism</i> , 1990, 33, 685-692.	6.7	11
132	No Xenotropic Murine Leukemia Virus-related Virus Detected in Fibromyalgia Patients. <i>Emerging Infectious Diseases</i> , 2011, 17, 314-315.	4.3	11
133	DXA in the assessment of subchondral bone mineral density in knee osteoarthritis: A semi-standardized protocol after systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 275-283.	3.4	11
134	Inhibition of pSTAT1 by tofacitinib accounts for the early improvement of experimental chronic synovitis. <i>Journal of Inflammation</i> , 2019, 16, 2.	3.4	11
135	Modulation of the Inflammatory Process by Hypercholesterolemia in Osteoarthritis. <i>Frontiers in Medicine</i> , 2020, 7, 566250.	2.6	11
136	Differences between radiographic abnormalities of acromegalic arthropathy and those of osteoarthritis. <i>Arthritis and Rheumatism</i> , 1990, 33, 455-456.	6.7	10
137	Cartilage oligomeric matrix protein (COMP) is modified by intra-articular liposomal clodronate in an experimental model of arthritis. <i>Clinical and Experimental Rheumatology</i> , 2006, 24, 622-8.	0.8	9
138	Antifibroproliferative effect of tenidap in chronic antigen-induced arthritis. <i>Arthritis and Rheumatism</i> , 1997, 40, 2147-2156.	6.7	8
139	Expression of the peptide C4b-binding protein \hat{A} in the arthritic joint. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1279-1285.	0.9	8
140	The reverse glucosamine sulfate pathway: application in knee osteoarthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 215-225.	1.8	8
141	Improvement of experimental accelerated atherosclerosis by chondroitin sulphate. <i>Osteoarthritis and Cartilage</i> , 2010, 18, S12-S16.	1.3	8
142	6- ϵ -Shogaol (enexasogol) treatment improves experimental knee osteoarthritis exerting a pleiotropic effect over immune innate signalling responses in chondrocytes. <i>British Journal of Pharmacology</i> , 2022, 179, 5089-5108.	5.4	8
143	LIMITED FORMS OF WEGENER'S GRANULOMATOSIS PRESENTING AS POLYMYALGIA RHEUMATICA. <i>Rheumatology</i> , 1991, 30, 382-384.	1.9	7
144	Is lecturing in Rheumatology Satellite Symposia a male attribute?. <i>Rheumatology International</i> , 2014, 34, 287-288.	3.0	7

#	ARTICLE	IF	CITATIONS
145	Elevated Plasma Fibronectin Levels in Rats with Immune and Toxic Glomerular Diseases. <i>Renal Failure</i> , 1990, 12, 227-232.	2.1	6
146	Aromatase expression in human chondrocytes: An induction due to culture. <i>Maturitas</i> , 2016, 85, 27-33.	2.4	6
147	Pulmonary Hemorrhage in Lupus Erythematosus Without Evidence of an Immunologic Cause. <i>Archives of Internal Medicine</i> , 1985, 145, 2128.	3.8	5
148	Does oral glucosamine prevent subchondral bone loss in an animal model of osteoarthritis? Comment on the article by Wang et al. <i>Arthritis and Rheumatism</i> , 2008, 58, 635-635.	6.7	5
149	Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: caseâ€“control study. <i>Arthritis Research and Therapy</i> , 2014, 16, 436.	3.5	5
150	Defective function of the mononuclear phagocytic system in rats with chronic nephritis. Evidence of a decreased degradation of IgG aggregates by Kupffer cells. <i>Immunology</i> , 1988, 63, 87-92.	4.4	5
151	Postsalmonella reactive phenomena in 2 patients with ankylosing spondylitis: no modification of the underlying disease. <i>Journal of Rheumatology</i> , 1990, 17, 250-1.	2.0	5
152	Blocking chondrocyte hypertrophy in conditional <i>Evc</i> knockout mice does not modify cartilage damage in osteoarthritis. <i>FASEB Journal</i> , 2022, 36, e22258.	0.5	5
153	Studies of Piroxicam Absorption by Oral Mucosa. <i>Arzneimittelforschung</i> , 2002, 52, 385-387.	0.4	4
154	Glucosamine sulfate for knee osteoarthritis: science and evidence-based use. <i>Therapy: Open Access in Clinical Medicine</i> , 2010, 7, 591-604.	0.2	4
155	Randomized clinical trials as reflexiveâ€“interpretative process in patients with rheumatoid arthritis: a qualitative study. <i>Rheumatology International</i> , 2015, 35, 1423-1430.	3.0	4
156	Validation of Musculoskeletal Ultrasound in the Assessment of Experimental Gout Synovitis. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 1516-1524.	1.5	4
157	Treating osteoporotic osteoarthritis, or the art of cutting a balding man's hair. <i>Osteoarthritis and Cartilage</i> , 2020, 28, 239-241.	1.3	4
158	Adenosine Deaminase as a Biomarker of Tenofovir Mediated Inflammation in Na ⁺ -ve HIV Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3590.	4.1	4
159	Use of crystalline glucosamine sulfate in osteoarthritis. <i>Future Rheumatology</i> , 2006, 1, 397-414.	0.2	3
160	Subchondral bone remodelling and osteoarthritis. <i>Arthritis Research and Therapy</i> , 2012, 14, .	3.5	3
161	Chondroitin sulfate â€” CONCEPT clear, uncertainties unchanged. <i>Nature Reviews Rheumatology</i> , 2017, 13, 576-577.	8.0	3
162	Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyradamole and Adenosine A2A Receptor. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11490.	4.1	3

#	ARTICLE	IF	CITATIONS
163	PAF, a potent proinflammatory mediator, looking for its role in the pathogenesis of joint damage. Annals of the Rheumatic Diseases, 1997, 56, 211-213.	0.9	2
164	HLA-B27 in patients with a permanent pacemaker. Annals of the Rheumatic Diseases, 2003, 62, 1018-1018.	0.9	2
165	244 OSTEOARTHRITIS LEADS TO INCREASED LEVELS OF PROTEIN O-LINKED N-ACETYLGLUCOSAMINE IN THE CARTILAGE. Osteoarthritis and Cartilage, 2010, 18, S111-S112.	1.3	2
166	Study of the O-linked-N-acetyl-glucosaminylation of proteins induced by high doses of glucosamine and its correlation with osteoarthritis progression. Osteoarthritis and Cartilage, 2012, 20, S126.	1.3	2
167	<p>It Is the Time to Think About a Treat-to-Target Strategy for Knee Osteoarthritis</p>. Therapeutics and Clinical Risk Management, 2019, Volume 15, 1479-1482.	2.0	2
168	Joint obesity as a pathogenic factor in osteoarthritis. Osteoarthritis and Cartilage, 2021, 29, 1239-1241.	1.3	2
169	Pulmonary infiltrates and abdominal colic pain in a patient with a connective tissue disorder. Annals of the Rheumatic Diseases, 2000, 59, 15-19.	0.9	1
170	Viscosupplementation for Osteoarthritis of the Knee. Annals of Internal Medicine, 2013, 158, 74.	3.9	1
171	Estrogen-Dependent Transcriptional Activity: A Protection Against ROS in Osteoarthritis. , 2013, , 369-391.		1
172	References from the classical rheumatologic literature. Arthritis and Rheumatism, 1985, 28, 1320-1320.	6.7	0
173	Protein-losing enteropathy caused by systemic lupus erythematosus. Gut, 1985, 26, 757-758.	12.1	0
174	Grado de conocimiento de la osteoporosis en mujeres posmenopáusicas. Revista Española De Enfermedades Metabólicas Áreas, 2008, 17, 71-75.	0.0	0
175	Do Clinical Practice Guidelines Do Enough to Help Clinicians Identify Patients at High Risk of Osteoporotic Fracture?. Journal of Clinical Rheumatology, 2011, 17, S57.	0.9	0
176	¿Osteoimmunología, osteo-reumatología o reumatología sin más?. Reumatología Clínica, 2013, 9, 257-258.	0.5	0
177	Reply. Arthritis and Rheumatology, 2017, 69, 2093-2094.	5.6	0
178	Does anti-tumour necrosis factor alpha therapy exert a long-term structural benefit in hand osteoarthritis?. Rheumatology, 2018, 57, 1879-1880.	1.9	0
179	Response to: “Correspondence on “Glucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation?” by Angelides and Manolios. Annals of the Rheumatic Diseases, 2021, , annrheumdis-2020-219721.	0.9	0